143 related articles for article (PubMed ID: 29446163)
1. Do we have enough evidence for recommending therapeutic plasma exchange for patients with natalizumab-associated progressive multifocal leukoencephalopathy?
Pham HP; Raju D; Schwartz J
J Clin Apher; 2018 Jun; 33(3):452-453. PubMed ID: 29446163
[No Abstract] [Full Text] [Related]
2. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
Maloney E; Molloy A; Al Hussona M; O'Donnell L; Killeen R; McGuigan C
J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
[No Abstract] [Full Text] [Related]
3. To PLEX or not to PLEX in natalizumab-associated PML.
Tyler KL; Vollmer TL
Neurology; 2017 Mar; 88(12):1108-1109. PubMed ID: 28228561
[No Abstract] [Full Text] [Related]
4. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
[TBL] [Abstract][Full Text] [Related]
5. [Natalizumab can induce progressive multifocal leucoencephalopathy].
Theódórsdóttir A; Blaabjerg M; Falah M
Ugeskr Laeger; 2014 Aug; 176(35):. PubMed ID: 25293706
[TBL] [Abstract][Full Text] [Related]
6. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
7. Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Hodel J; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Pruvo JP; Vermersch P; Leclerc X
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2296-302. PubMed ID: 26316568
[TBL] [Abstract][Full Text] [Related]
8. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
Hervás JV; Presas-Rodríguez S; Crespo-Cuevas AM; Canento T; Lozano-Sánchez M; Massuet-Vilamajó A; Ramo-Tello C
Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
[TBL] [Abstract][Full Text] [Related]
9. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D
Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
[No Abstract] [Full Text] [Related]
10. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
Zhang Y; Wright C; Flores A
J Med Case Rep; 2018 Jul; 12(1):187. PubMed ID: 29960601
[TBL] [Abstract][Full Text] [Related]
11. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
[TBL] [Abstract][Full Text] [Related]
12. PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
Mowry EM; McArthur JC
Neurology; 2017 Mar; 88(12):1110-1111. PubMed ID: 28228562
[No Abstract] [Full Text] [Related]
13. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
Pitarokoili K; Gold R
Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
[No Abstract] [Full Text] [Related]
14. Editorial for JNV issue on PML.
Berger JR
J Neurovirol; 2015 Dec; 21(6):599-600. PubMed ID: 26329137
[No Abstract] [Full Text] [Related]
15. Natalizumab-related PML 2 weeks after negative anti-JCV antibody assay.
Gagne Brosseau MS; Stobbe G; Wundes A
Neurology; 2016 Feb; 86(5):484-6. PubMed ID: 26740679
[No Abstract] [Full Text] [Related]
16. Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?
Mancinelli CR; Scarpazza C; Santuccio G; De Rossi N; Capra R
Neurol Sci; 2018 May; 39(5):965-966. PubMed ID: 29302813
[No Abstract] [Full Text] [Related]
17. Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
Lauda F; Fangerau T; Javaheripour-Otto K; Pinkhardt E; Kassubek J; Tumani H
J Neurol; 2015; 262(4):1055-7. PubMed ID: 25663412
[No Abstract] [Full Text] [Related]
18. Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay.
Campagnolo D; Dong Q; Lee L; Ho PR; Amarante D; Koendgen H
J Neurovirol; 2016 Dec; 22(6):880-881. PubMed ID: 27730447
[No Abstract] [Full Text] [Related]
19. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
Yap SM; McGuigan C
Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
[No Abstract] [Full Text] [Related]
20. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
Rath L; Vijiaratnam N; Skibina O
Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
